HMTX.F Stock Overview

A clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. More details

HMTX.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Shareholders have been substantially diluted in the past year

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Hemostemix Inc. Competitors

iBio

NasdaqCM:IBIO

US$8.4m

Aprea Therapeutics

NasdaqCM:APRE

US$9.2m

Sensei Biotherapeutics

NasdaqCM:SNSE

US$9.9m

Ernexa Therapeutics

NasdaqCM:ERNA

US$10.8m

Price History & Performance

Summary of share price highs, lows and changes for Hemostemix
Historical stock prices
Current Share Price	CA$0.067
52 Week High	CA$0.28
52 Week Low	CA$0.024
Beta	-0.58
1 Month Change	-0.67%
3 Month Change	-63.40%
1 Year Change	n/a
3 Year Change	-75.81%
5 Year Change	-51.59%
Change since IPO	-99.51%

Recent updates

Shareholder Returns

	HMTX.F	US Biotechs	US Market
7D	2.8%	-6.1%	1.3%
1Y	n/a	-13.2%	8.2%

Return vs Industry: Insufficient data to determine how HMTX.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HMTX.F performed against the US Market.

Price Volatility

Is HMTX.F's price volatile compared to industry and market?
HMTX.F volatility
HMTX.F Average Weekly Movement	24.2%
Biotechs Industry Average Movement	11.9%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	4.1%

Stable Share Price: HMTX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: HMTX.F's weekly volatility has decreased from 38% to 24% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Thomas Smeenk	hemostemix.com

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Hemostemix Inc. Fundamentals Summary

How do Hemostemix's earnings and revenue compare to its market cap?
HMTX.F fundamental statistics
Market cap	US$9.92m
Earnings (TTM)	-US$1.88m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-5.3x

P/E Ratio

Is HMTX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HMTX.F income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$2.62m
Earnings	-CA$2.62m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.018
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-68.5%

How did HMTX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/09 08:35
End of Day Share Price	2025/05/05 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Siddharth Rajeev	Fundamental Research Corp.